Global Cell Therapy for Solid Tumor Market Strategic Research Report

Scope of the Report

The global Cell Therapy for Solid Tumor market size is predicted to grow from US$ 1,971 million in 2025 to US$ 7,851 million in 2032; it is expected to grow at a CAGR of 20.9% from 2026 to 2032.

Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.

Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from “conceptually feasible” to “clinically translatable and commercially actionable.” Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.

The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.

Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from “whether it works” to “which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.” Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.

This report presents a comprehensive overview of the global Cell Therapy for Solid Tumor market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• CAR-T Therapy
• TCR-T Therapy
• TIL Therapy
• CAR-NK Therapy
• Tumor-Infiltrating NK Or T Cells
• Other

Segment by Cell Source

• Autologous Therapy
• Allogeneic Therapy
• Gene-Edited Therapy
• Armored Cell Therapy
• Combination Therapy
• Other

Segment by Indication

• Melanoma Products
• Gastrointestinal Tumor Products
• Liver Cancer Products
• Lung Cancer Products
• Gynecologic Tumor Products
• Other

Segment by Application

• Melanoma
• Lung Cancer
• Liver Cancer
• Gastric And Colorectal Cancer
• Ovarian Cancer
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cell Therapy for Solid Tumor market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Melanoma, Lung Cancer, Liver Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact